Glenview Trust Co raised its stake in CVS Health Corp (NYSE:CVS) by 9.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,414 shares of the pharmacy operator’s stock after buying an additional 8,476 shares during the quarter. Glenview Trust Co’s holdings in CVS Health were worth $8,079,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Pathstone Family Office LLC boosted its holdings in CVS Health by 341.0% during the 2nd quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock valued at $2,353,000 after acquiring an additional 982 shares during the period. TB Alternative Assets Ltd. purchased a new position in CVS Health during the 2nd quarter valued at about $121,000. Gemmer Asset Management LLC boosted its holdings in CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after acquiring an additional 200 shares during the period. Captrust Financial Advisors purchased a new position in CVS Health during the 2nd quarter valued at about $155,000. Finally, SRS Capital Advisors Inc. boosted its holdings in CVS Health by 48.2% during the 1st quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock valued at $177,000 after acquiring an additional 734 shares during the period. Institutional investors own 82.24% of the company’s stock.

A number of brokerages recently commented on CVS. Royal Bank Of Canada began coverage on CVS Health in a report on Tuesday, September 19th. They set an “outperform” rating and a $95.00 target price for the company. Jefferies Group raised their target price on CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a report on Friday, September 15th. Needham & Company LLC restated a “hold” rating on shares of CVS Health in a report on Sunday, September 10th. Wolfe Research lowered CVS Health from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $89.00 to $82.00 in a research report on Monday, August 14th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $90.00 price target on shares of CVS Health in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $86.35.

In other CVS Health news, EVP Thomas M. Moriarty sold 90,267 shares of CVS Health stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total transaction of $7,186,155.87. Following the transaction, the executive vice president now owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Thomas M. Moriarty sold 20,547 shares of CVS Health stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the transaction, the executive vice president now directly owns 43,178 shares in the company, valued at approximately $3,504,758.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 714,125 shares of company stock worth $58,119,381. 0.61% of the stock is currently owned by corporate insiders.

Shares of CVS Health Corp (NYSE:CVS) traded down $0.68 during midday trading on Wednesday, hitting $71.01. The stock had a trading volume of 15,423,900 shares, compared to its average volume of 6,880,704. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.72. The firm has a market cap of $72,621.40, a price-to-earnings ratio of 12.56, a PEG ratio of 1.23 and a beta of 0.89.

CVS Health (NYSE:CVS) last issued its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same quarter last year, the company earned $1.64 EPS. The business’s quarterly revenue was up 3.5% on a year-over-year basis. sell-side analysts forecast that CVS Health Corp will post 5.9 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Glenview Trust Co Has $8.08 Million Holdings in CVS Health Corp (CVS)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/glenview-trust-co-has-8-08-million-holdings-in-cvs-health-corp-cvs/1747331.html.

CVS Health Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.